Gilead Sciences Inc. (Nasdaq: GILD) stock hit a 52-week high of $92.97 this morning (Thursday) after the company crushed earnings estimates last night. At that price, the stock was up 3% from yesterday's closing price.
Money Morning’s Defense and Tech Specialist Michael Robinson has been high on GILD stock for some time, and yesterday’s huge earnings beat comes as no surprise to Money Morning readers. Here’s why this hot biotech stock is just getting started.
Puma Biotech (NYSE: PBYI) Stock Skyrockets 300% on Breast Cancer Breakthrough
This is not a misprint: Puma Biotechnology Inc. (NYSE: PBYI) stock surged nearly 300%, or $176.63, to an all-time high of $234.99 intraday Wednesday.
Founded in 2010 and based in Los Angeles, Puma doesn't have a single drug yet on the market.But’s that’s likely to change now... see why this is among the hot biotech stocks to watch now.
Our Best Stocks to Buy List: New Top Picks in Bioscience, Energy, and More
Best stocks to buy for the week ending July 4, 2014: Last week, we covered a "catalyst" that could spark a share-price rally for what is already one of the best stocks to buy, three recommendations to take advantage of rising oil prices, and a way to tap into big profits in an "other" bioscience niche that is less risky but highly lucrative.Get these, plus the top healthcare picks, dividend stocks, and more, in the full list of our best stocks to buy now.
The BioScience Profit Outlook for the Rest of 2014
With just six months left on my 2014 bioscience "profit calendar," things are really starting to look promising for the second half of 2014. There are huge opportunities in several subsectors of the bioscience market in particular.
That said, some bioscience analysts are saying there's a bubble. And it's scaring a lot of bioscience investors out of great positions in the market.
That's why last week I shared my complete bioscience market outlook for the rest of 2014 with my paid members - to help them see the real market story.
Today I want to share with you some of my thinking, expectations, and predictions, as well as my strategy to get us tapped in to a segment of the bioscience market we haven't even touched yet.
This segment has been tremendously profitable for some of the world's biggest drug companies, and I think there are going to be some killer profits for us there, too... Full StoryRead More...
IPO Calendar 2014: AMBX Leads Healthcare-Heavy Week
IPO Calendar 2014 update: This year, 212 companies have already held IPOs, and the healthcare industry has seen more companies go public than any sector.
Through Monday, 51 healthcare companies have made initial public offerings, accounting for 24% of the total U.S. IPO market.
Healthcare stocks are once again at the forefront of the IPO calendar this week as five of this week's seven IPOs are healthcare companies.Here's a look at each company hitting the market this week, and the story behind each deal...
How to Tap Big Profits in That "Other" Bioscience Niche
At first glance, it may seem like bioscience investing is so complicated and risky that it's hardly worth your time and money to invest, at least if you don't have someone knowledgeable to guide you.
And it's true. Putting your money behind new, experimental drugs, without some guidance, is a crapshoot.
But there's an approach to making profits from this sector that doesn't rely on breakthrough discoveries, expensive drug trials, or constant cash infusions through dilutive public offerings to fuel its engine.
That's what makes the company we'll look at today such an attractive investment.
Welcome to the lucrative world of generics... Full Story
VRTX, ABT, AAPL Among Hot Stocks to Watch Today
Vertex Pharmaceuticals Inc. (Nasdaq: VRTX) tops Tuesday's hot stocks to watch list. Shares skyrocketed 50% intraday after the biotech company deemed its cystic fibrosis treatment a success.
Also landing on today's hot stocks list are a number of penny stocks, a semiconductor company, and several stocks moving up on analysts' action and M&A activity.Check out 12 of Tuesday’s movers – including VRTX, AAPL, and ABT – and find out what’s behind their action…
This Is the Best Way to Profit from the Biotech Stocks Rebound
Late last month, I told you that biotech is one of the best ways to profit from the tech rebound.
Somewhat ironically, a rollover in biotech stocks was one of the proximate causes of the overall sell-off in tech earlier this year.
And now I'm recommending that you invest in the company that purportedly "caused" the biotech market to roll over in the first place.That’s because the company, Gilead Sciences Inc. (Nasdaq: GILD), will be the biggest beneficiary of biotech’s comeback…
Best Stocks to Buy: Cash In on a New $35 Billion Biotech Market
Each week our Money Morning experts dish out the latest profit plays - and asset-protection moves - for our Money Morning Members - all for free.
Last week, Money Morning's best stocks to buy included five biotech picks. Four of them are blazing trails in immuno-oncology. Our fifth biotech pick has already tripled in value in the last six months, and it's not done yet.
Aside from these biotech winners, we covered an ETF play on the European Central Bank's recent policy changes, the best stock in "unified computing," and a smart gold buy at a discount.Get these plus more of our latest, best stocks to buy.
Stocks to Buy: Intercept Pharma (Nasdaq: ICPT) Ready to Double
Usually the best stocks to buy have not already tripled in value within the past six months.
But then there's Intercept Pharmaceuticals Inc. (Nasdaq: ICPT).
This biotech stock soared more than 500% in two days on the news its innovative and promising hepatitis drug obeticholic acid, or OCA, had a trial stopped early because the drug met the goals of the study.
Bulls have refused to be distracted by some negative news that has pushed the stock back under $300 in the meantime.The crazy thing is, Intercept Pharma could actually double from here...
The Secret to Making Money from Bioscience's "Scariest Event"
In bioscience investing, binary catalysts are milestone events that signal a thumbs-up or thumbs- down for an experimental drug as it makes its way through the regulatory process.
Positive catalysts can send a share price soaring. Negative ones can send it into a nosedive.
Perhaps the least understood of these catalysts are FDA Advisory Committee (a.k.a. AdCom) recommendations.
But they're also among the most powerful.
Here's what I mean, and how to play them profitably... Full StoryRead More...
Seven Biotech Stocks to Watch Based on "Game-Changing" Cancer Treatment Updates
A number of promising cancer treatments were presented this week by key global pharmaceutical players at the 2014 Annual Meeting of the American Society of Clinical Oncology (ASCO) - which is why this is a key time of year to watch a specific group of biotech stocks.
The event, which this year took place May 30 - June 3, is attended by thousands of renowned oncologists, researchers, analysts, and investors. It is unquestionably the most highly anticipated and most news-generating cancer research meeting of the year.
ASCO can deliver a blockbuster, breakout drug that will not only lead to better cancer treatments, but one that will also bring in billions of dollars in revenue. Moreover, there's also the potential of a drug's developer becoming a profitable takeover target.Check out this list of biotech stocks to watch post-ASCO.
The Four Telltale Signs of a Bioscience "Blockbuster" in the Making
The FDA's Expedited Programs help get promising new therapies for seriously ill patients approved as soon as possible.
But they also create an unintended side effect that's a huge advantage for investors: They point exactly to the biggest money-making opportunities in the bioscience industry.
They're like big, green, neon signs that say, "This is an important drug with incredible profit potential."
And this is how you find them... Full StoryRead More...
Why Tesaro (Nasdaq: TSRO) Stock Is Surging Today
Shares of Tesaro Inc. (Nasdaq: TSRO) stock were up 23% today (Monday) after the company announced that its drug rolapitant met the main goal of its third and final Phase 3 trial.
According to Money Morning's BioScience Investment Specialist Ernie Tremblay, volatility like that of TSRO stock is common among biotech companies with late stage drug candidates.Here's what investors should expect from this hot biotech stock now...